Newsfeeds - Spark Newswire

1 minute read

Bristol-Myers Squibb Q3 EPS $1.99 Beats $1.83 Estimate, Sales $11.22B Beat $11.19B Estimate

Today, 8:55 PM

Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.83 by 8.74 percent. This is a 0.5 percent decrease over earnings of $2.00 per share from the

BMY

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 8:55 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABT

1 minute read

News

President Biden to Sign Executive Order Seeking New Prescription Drug Cost Savings

By Charles Gross

Today, 8:55 PM

-Reuters Citing Official https://www.reuters.com/world/us/biden-sign-order-seeking-new-prescription-drug-cost-savings-official-2022-10-14/

AZN

2 minute read

Peering Into Bristol-Myers Squibb’s Recent Short Interest

By Benzinga Insights

Today, 8:55 PM

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 4.63% since its last report. The company recently reported that it has 24.18 million shares sold short, which is 1.13% of all regular shares that are available for trading.

BMY

1 minute read

Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $66

By Benzinga Newsdesk

Today, 8:55 PM

Barclays analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $69 to $66.

BMY

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb

By Benzinga Insights

Today, 8:55 PM

Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings:

BMY

2 minute read

Will Chart Analysts Notice Bad Omen on Bristol-Myers Squibb’s Chart

By Benzinga Insights

Today, 8:55 PM

If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb (NYSE:BMY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

BMY

1 minute read

PureTech Health Confirms ‘Possible’ Merger With Nektar Therapeutics

By Vandana Singh

Today, 8:55 PM

PureTech Health plc (NASDAQ:PRTC) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR). In April, Nektar Therapeutics…

BMY

1 minute read

Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System

By Vandana Singh

Today, 8:55 PM

Autolus Therapeutics plc (NASDAQ:AUTL) has entered into an agreement with Bristol-Myers Squibb Co (NYSE:BMY). The agreement grants Bristol Myers Squibb access to incorporate Autolus’…

AUTL

2 minute read

Exelixis Expands Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Include Fixed-Dose Combination Of Nivolumab And Relatlimab In Combination With XL092 In Phase 1b STELLAR-002 Trial

By Bill Haddad

Today, 8:55 PM

Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor — ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) today announced the expansion of its June 2021

BMY